<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293720</url>
  </required_header>
  <id_info>
    <org_study_id>09-1E</org_study_id>
    <nct_id>NCT02293720</nct_id>
  </id_info>
  <brief_title>An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System</brief_title>
  <acronym>OLE</acronym>
  <official_title>An Open-Label Extension to Protocol 09-1, Multi-Center, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GI Dynamics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, single-arm, open-label study to evaluate the safety and effectiveness of the&#xD;
      EndoBarrier Gastrointestinal Liner System liner on glycemic control in control subjects from&#xD;
      study #09-1 who are not treatment failures and have completed 12 months of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label extension study for subjects who participated in the control arm of&#xD;
      study #09-1 (A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the&#xD;
      EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately&#xD;
      Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents) who are not treatment&#xD;
      failures and completed 12 months of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This was the cross over study for 09-1 which was terminated early&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in HbA1c value from baseline to 12 months</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes in HbA1c from baseline to 12 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the incidence of device related serious adverse events requiring an early removal</measure>
    <time_frame>52 weeks</time_frame>
    <description>Demonstrated to be less than or equal to 15%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>EndoBarrier Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who participated in the control arm of study #09-1 who are not treatment failures and have completed 12 months of the study. These subjects will have the EndoBarrier device implanted for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoBarrier</intervention_name>
    <description>The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.</description>
    <arm_group_label>EndoBarrier Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Control subjects from study # 09-1 who are not treatment failures and have completed&#xD;
             12 months of the study&#xD;
&#xD;
          2. Age ≥21 years and ≤ 65 years&#xD;
&#xD;
          3. Have signed an informed consent form within 30 days of week 52 visit in study #09-1.&#xD;
&#xD;
          4. HbA1c ≥ 7.5% and ≤ 10%&#xD;
&#xD;
          5. Stable (s) doses (up to 2) of anti -diabetes medication(s) for a minimum of 3 months&#xD;
             prior to enrollment with at least one at minimum required dose as outlined below:&#xD;
&#xD;
               1. MET (≥1500 mg/day) OR&#xD;
&#xD;
               2. SU (based on doses specified below) Generic Name (brand name) minimum required&#xD;
                  dose&#xD;
&#xD;
                  Glimepiride (Amaryl) 4 (mg/day) Glipizide (Glucotrol) 20 (mg/day) Glipizide&#xD;
                  (Glucotrol XL) 10 (mg/day) Glyburide (Micronas, Diabeta) 10 (mg/day) Micronized&#xD;
                  Glyburide (Glynase) 6 (mg/day) Chlorpropamide (Diabinese) 350 (mg/day) Tolazamide&#xD;
                  (Tolinase 500 (mg/day) Tolbutamide (Orinase) 1500 (mg/day) OR&#xD;
&#xD;
               3. DPP-4i (based on doses specified below) Generic Name (brand name) minimum&#xD;
                  required dose Sitagliptin (Januvia®) 50 (mg/day) Saxagliptin (Onglyza®) 2.5&#xD;
                  (mg/day) Linagliptin (Tradjenta ®) 5 (mg/day) Alogliptin (Nesina®) 12.5 (mg/day)&#xD;
&#xD;
               4. TZD (based on doses specified below) Generic Name (brand name) minimum required&#xD;
                  dose Rosiglitazone (Avandia®) 4 (mg/day) Pioglitazone (Actos®) 30 (mg/day)&#xD;
&#xD;
          6. BMI ≥ 30 and ≤ 55&#xD;
&#xD;
          7. Willing to comply with study requirements&#xD;
&#xD;
          8. Documented negative pregnancy test in women of childbearing potential&#xD;
&#xD;
          9. Women of childbearing potential not intending to become pregnant for the duration of&#xD;
             their trial participation&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Any change from the subject's previous health status from assessment for eligibility&#xD;
             in pivotal trial phase (such as a new condition or major illness) that places the&#xD;
             subject at undue risk by participating in the study&#xD;
&#xD;
          2. C-peptide &lt; 1.0 ng/mL&#xD;
&#xD;
          3. Triglyceride level &gt; 400 mg/dL&#xD;
&#xD;
          4. Vitamin D deficiency (&lt;20ng/ml)&#xD;
&#xD;
          5. Male subjects with serum Cr &gt;1.5 mg/dl or female subjects with Cr &gt;1.4 mg/dl&#xD;
&#xD;
          6. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet&#xD;
             count less than 100,000/microliter, or known coagulopathy&#xD;
&#xD;
          7. Symptomatic kidney stones or gallstones within 6 months prior to baseline (within 30&#xD;
             days of week 52 visit from #09-1 study)&#xD;
&#xD;
          8. Acute pancreatitis at the time of baseline (within 30 days of week 52 visit from #09-1&#xD;
             study)&#xD;
&#xD;
          9. Diagnosis of osteoporosis or currently taking bisphosphonates or teriparatide&#xD;
&#xD;
         10. Currently taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g. aspirin,&#xD;
             ibuprofen, etc.) within 10 days of the procedure and/or there is a need or expected&#xD;
             need to use during the trial 12 months post index procedure&#xD;
&#xD;
         11. Currently taking prescription antithrombotic therapy (e.g. anticoagulant or&#xD;
             antiplatelet agent) within 10 days prior to the procedure and/or there is a need or&#xD;
             expected need to use during the trial 12 months post index procedure&#xD;
&#xD;
         12. Currently taking the following medications (at the time of enrollment) and/or there is&#xD;
             a need or expected need to use these medications during the trial 12 months post index&#xD;
             procedure:&#xD;
&#xD;
             Restricted Medications/Supplements Systemic corticosteroids Drugs known to affect GI&#xD;
             motility (e.g. Reglan) Prescription or over-the-counter weight loss medication(s)&#xD;
             Medications known to cause significant weight gain (refer to study reference manual&#xD;
             (SRM) or weight loss (e.g. chemotherapeutics)&#xD;
&#xD;
         13. Currently taking ≥ two of the following medications for type 2 diabetes; MET, SU,&#xD;
             DDP-4i and TZD at baseline (within 30 days of week 52 visit from #09-1 study)&#xD;
&#xD;
         14. Currently taking medications for type 2 diabetes other than MET, SU, DPP-4i, and TZD&#xD;
             (e.g. GLP1 or insulin) at baseline (within 30 days of week 52 visit from #09-1 study)&#xD;
&#xD;
         15. Chronic use of narcotics, opiates, or benzodiazepines and other addictive&#xD;
             tranquilizers&#xD;
&#xD;
         16. Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, and all&#xD;
             equivalent antibiotics&#xD;
&#xD;
         17. Active H. pylori (Note: Subjects may be eligible after undergoing 2 weeks of&#xD;
             antibiotic treatment without re-screening)&#xD;
&#xD;
         18. Residing in a location without ready access to study site medical resources&#xD;
&#xD;
         19. Documented weight loss of &gt; 10 pounds anytime during the 3 months prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

